Emerging therapies for diabetic macular edema

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are effective in many patients. However, some patients continue to lose vision despite treatment. Emerging therapies may be divided into pharmacologic and surgical interventions. Pharmacologic therapies include locally administered agents, such as corticosteroids and VEGF antagonists, and systemically administered agents, such as ruboxistaurin. No medication is currently approved by the US FDA for the treatment of diabetic macular edema. Surgical approaches include pars plana vitrectomy techniques. As data from randomized clinical trials accumulate, the precise role for each of these therapies will emerge.

Original languageEnglish (US)
Pages (from-to)163-171
Number of pages9
JournalExpert Review of Ophthalmology
Volume4
Issue number2
DOIs
StatePublished - Sep 14 2009

    Fingerprint

Keywords

  • Diabetic macular edema
  • Pars plana vitrectomy
  • Randomized clinical trial
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology
  • Biomedical Engineering
  • Optometry

Cite this